IFR 300 and IFR 310, qRT PCR Diagnostic kit for Rheumatoid Arthritis (RA) patients that did not respond to the first line treatment which include Methotrexate and\or other anti inflammatory treatments. These diagnostic kits requires a single blood sample measuring specific PGES allowing treatment succession probability prediction for expensive ($15K-$30K), second line biological treatments: anti TNFα (Remicade, Enbrel, Humira etc.) or B cell depletion (Rituximab,) or anti IL6 drugs.
IFR 300 and 310 are in the end of prospective clinical trials and will be available for use in the next months. A poster showing Genefron IFR300 results was published in the November 2015 ACR conference.